-5%
Brezofil contains Doxophylline, a bronchodilator with a distinct molecular structure featuring a dioxolane group at position 7. Unlike Theophylline, it selectively inhibits phosphodiesterase 4 (PDE4), leading to bronchial smooth muscle relaxation.
🔬 Key benefits of Doxophylline:
✔ Lower affinity for adenosine A1 and A2 receptors, ensuring a better safety profile.
✔ Inhibits platelet-activating factor (PAF) and reduces leukotriene production, helping in airway inflammation control.
Brezofil is prescribed for the treatment of the following respiratory conditions:
✅ Bronchial asthma
✅ Bronchospasm
✅ Chronic obstructive pulmonary disease (COPD)
✅ Pulmonary diseases with a spastic bronchial component